Search
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Synonyms: 1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane, N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalBelinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-, (2E)-Lobeline
go.drugbank.com/drugs/DB05137InvestigationalIt has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Categories: Heterocyclic Compounds, 1-RingPretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalPersistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. … It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVintafolide
go.drugbank.com/drugs/DB05168InvestigationalVintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Categories: Heterocyclic Compounds, 2-RingBezisterim
go.drugbank.com/drugs/DB05212InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAmibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Categories: Adrenergic beta-3 Receptor AgonistsLarazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Synonyms: GLYCINE, GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYL-, GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYLGLYCINEApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and
Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substrates